JP2021527128A - 組織石灰化を予防または治療するための方法および組成物 - Google Patents

組織石灰化を予防または治療するための方法および組成物 Download PDF

Info

Publication number
JP2021527128A
JP2021527128A JP2021518056A JP2021518056A JP2021527128A JP 2021527128 A JP2021527128 A JP 2021527128A JP 2021518056 A JP2021518056 A JP 2021518056A JP 2021518056 A JP2021518056 A JP 2021518056A JP 2021527128 A JP2021527128 A JP 2021527128A
Authority
JP
Japan
Prior art keywords
subject
mkh2
administration
stopping
calcification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021518056A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527128A5 (https=
JPWO2019237053A5 (https=
Inventor
ジェイムズ・エイ・タムリン
ポール・エル・ダーク
ジョン・エム・ルディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epizon Pharma Inc
Original Assignee
Epizon Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizon Pharma Inc filed Critical Epizon Pharma Inc
Publication of JP2021527128A publication Critical patent/JP2021527128A/ja
Publication of JP2021527128A5 publication Critical patent/JP2021527128A5/ja
Publication of JPWO2019237053A5 publication Critical patent/JPWO2019237053A5/ja
Priority to JP2024043503A priority Critical patent/JP7847880B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021518056A 2018-06-08 2019-06-07 組織石灰化を予防または治療するための方法および組成物 Pending JP2021527128A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024043503A JP7847880B2 (ja) 2018-06-08 2024-03-19 組織石灰化を予防または治療するための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682796P 2018-06-08 2018-06-08
US62/682,796 2018-06-08
PCT/US2019/036138 WO2019237053A1 (en) 2018-06-08 2019-06-07 Methods and compositions for preventing or treating tissue calcification

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024043503A Division JP7847880B2 (ja) 2018-06-08 2024-03-19 組織石灰化を予防または治療するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2021527128A true JP2021527128A (ja) 2021-10-11
JP2021527128A5 JP2021527128A5 (https=) 2022-06-10
JPWO2019237053A5 JPWO2019237053A5 (https=) 2022-06-10

Family

ID=68765387

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021518056A Pending JP2021527128A (ja) 2018-06-08 2019-06-07 組織石灰化を予防または治療するための方法および組成物
JP2024043503A Active JP7847880B2 (ja) 2018-06-08 2024-03-19 組織石灰化を予防または治療するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024043503A Active JP7847880B2 (ja) 2018-06-08 2024-03-19 組織石灰化を予防または治療するための方法および組成物

Country Status (11)

Country Link
US (8) US10688064B2 (https=)
EP (1) EP3801477A4 (https=)
JP (2) JP2021527128A (https=)
KR (1) KR20210018423A (https=)
CN (1) CN113038940A (https=)
AU (1) AU2019282420B2 (https=)
CA (1) CA3102977A1 (https=)
IL (1) IL279245B2 (https=)
MX (2) MX2020013302A (https=)
SG (1) SG11202012070YA (https=)
WO (1) WO2019237053A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019237054A1 (en) 2018-06-08 2019-12-12 Epizon Pharma, Inc. Methods and compositions for preventing or treating calciphylaxis
MX2020013302A (es) 2018-06-08 2021-05-12 Epizon Pharma Inc Métodos y composiciones para prevenir o tratar calcificación de tejido.
US10822295B2 (en) * 2018-09-12 2020-11-03 Epizon Pharma, Inc. Menaquinol compositions and methods of treatment
US20220160652A1 (en) * 2019-03-12 2022-05-26 Kaydence Pharma As Use of vitamin k in combination with anticoagulants
EP4367131A1 (en) * 2021-07-05 2024-05-15 Universiteit Maastricht Means and methods for the treatment of calcium crystal deposition diseases
WO2023129413A1 (en) * 2021-12-31 2023-07-06 Ingredient Fusion, Llc Molecular complexing method, formulation and manufacturing for enhanced nutrient delivery
WO2024071848A1 (ko) * 2022-09-27 2024-04-04 경북대학교 산학협력단 혈관석회화 치료제 스크리닝 방법
WO2025075468A1 (ko) * 2023-10-06 2025-04-10 주식회사 레드엔비아 혈관 또는 판막 협착증의 예방 또는 치료용 병용제제

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016131993A2 (en) * 2015-02-20 2016-08-25 Vitak B.V. Vitamin k and capillary function

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176778A1 (en) * 2001-08-03 2005-08-11 Vitak Bv Isoprenyl derivatives and their use in the title treatment and prevention of osteoporosis and cardiovascular calcification
WO2005030190A1 (en) * 2003-09-26 2005-04-07 Natural Asa Natural menaquinone 7 compositions
DE602006020658D1 (de) 2005-06-03 2011-04-28 Nattopharma Asa Verwendung von Vitamin K, um die Verkalkung der Blutgefässe rückgängig zu machen
NZ574882A (en) 2006-07-14 2012-08-31 Nattopharma Asa Pharmaceutical and nutraceutical products comprising vitamin k2
GB0817528D0 (en) 2008-09-24 2008-10-29 Syntavit As Process
BR112013009724A2 (pt) * 2010-11-01 2016-07-19 Viridis Biopharma Pvt Ltd equilíbrio dinâmico do sistemna nervoso autonômo utilizando a vitamina mk-7
GB201203705D0 (en) 2012-03-02 2012-04-18 Kappa Bioscience As Prodrugs
US10159787B2 (en) 2012-06-18 2018-12-25 Fresenius Kabi Deutschland Gmbh Port cannula system for puncturing port catheters
WO2014191466A1 (en) * 2013-05-28 2014-12-04 Nattopharma Asa Menaquinone supplementation and vascular health
GB201314245D0 (en) 2013-08-08 2013-09-25 Kappa Bioscience As Provitamins
BR112017019750A2 (en) 2015-03-20 2018-05-29 Gnosis S.P.A. process for preparing a crystalline form of menaquinol, crystalline form of menaquinol, process for preparing a solid form of menaquinol, pharmaceutical or nutraceutical composition and use of the crystalline form of menaquinol
IT201700085412A1 (it) 2017-07-26 2019-01-26 Pharmanutra S P A Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare
US10368858B1 (en) 2018-01-25 2019-08-06 Ring Orthopedics, Inc. Suture passer
WO2019237054A1 (en) 2018-06-08 2019-12-12 Epizon Pharma, Inc. Methods and compositions for preventing or treating calciphylaxis
MX2020013302A (es) 2018-06-08 2021-05-12 Epizon Pharma Inc Métodos y composiciones para prevenir o tratar calcificación de tejido.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016131993A2 (en) * 2015-02-20 2016-08-25 Vitak B.V. Vitamin k and capillary function

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BASAVAIAS RAVISHANKAR, ET AL.: "Safety assessment of menaquinone-7 for use in human nutrition", JOURNAL OF FOOD AND DRUG ANALYSIS, vol. 23, JPN6023015741, 2015, pages 99 - 108, ISSN: 0005201037 *
ROGIER CALUWE, ET AL.: "Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 29, JPN6023015740, 2014, pages 1385 - 1390, ISSN: 0005201036 *
SARAH L. BOOTH: "Roles for Vitamin K Beyond Coagulation", ANNUAL REVIEW OF NUTRITION, vol. 29, no. 1, JPN6023047019, 1 August 2009 (2009-08-01), pages 89 - 110, ISSN: 0005201038 *

Also Published As

Publication number Publication date
MX2024013515A (es) 2024-12-06
WO2019237053A1 (en) 2019-12-12
KR20210018423A (ko) 2021-02-17
JP7847880B2 (ja) 2026-04-20
IL279245B1 (en) 2023-11-01
CA3102977A1 (en) 2019-12-12
US10744101B2 (en) 2020-08-18
US12377060B2 (en) 2025-08-05
US20210093584A1 (en) 2021-04-01
EP3801477A1 (en) 2021-04-14
US20250302772A1 (en) 2025-10-02
MX2020013302A (es) 2021-05-12
US20200222337A1 (en) 2020-07-16
SG11202012070YA (en) 2021-01-28
AU2019282420A1 (en) 2021-01-07
US11033515B2 (en) 2021-06-15
CN113038940A (zh) 2021-06-25
US20210378986A1 (en) 2021-12-09
IL279245A (en) 2021-01-31
US10688064B2 (en) 2020-06-23
US10874623B2 (en) 2020-12-29
US10744102B2 (en) 2020-08-18
US20190374484A1 (en) 2019-12-12
IL279245B2 (en) 2024-03-01
JP2024073612A (ja) 2024-05-29
EP3801477A4 (en) 2022-02-23
US20200206158A1 (en) 2020-07-02
AU2019282420B2 (en) 2025-03-20
US20240009144A1 (en) 2024-01-11
US11723882B2 (en) 2023-08-15
US20200206159A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
JP7847880B2 (ja) 組織石灰化を予防または治療するための方法および組成物
US12433854B2 (en) Methods and compositions for preventing or treating calciphylaxis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220602

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230921

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231121